| 0.0322 0 (0%) | 05-22 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.04 | 1-year : | 0.04 |
| Resists | First : | 0.03 | Second : | 0.03 |
| Pivot price | 0.03 | |||
| Supports | First : | 0.03 | Second : | 0.02 |
| MAs | MA(5) : | 0.03 | MA(20) : | 0.03 |
| MA(100) : | 0.03 | MA(250) : | 0.19  |
|
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 0 | D(3) : | 0 |
| RSI | RSI(14): 43.6 | |||
| 52-week | High : | 1.76 | Low : | 0 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ TCON ] has closed Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 0.04 - 0.04 | 0.04 - 0.04 |
| Low: | 0.03 - 0.03 | 0.03 - 0.03 |
| Close: | 0.03 - 0.03 | 0.03 - 0.03 |
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.
Tue, 30 Jul 2024
TRACON Pharmaceuticals Announces it Will Wind Down Operations - GlobeNewswire
Tue, 30 Jul 2024
TRACON Pharmaceuticals Announces it Will Wind Down Operations - Stock Titan
Mon, 01 Jul 2024
TRACON Pharmaceuticals Announces Termination of ENVASARC - GlobeNewswire
Sat, 11 May 2024
TRACON Pharmaceuticals (TCON) Stock Forecast and Price Target 2025 - MarketBeat
Mon, 20 Nov 2023
TRACON Pharmaceuticals Announces License of Product Development Platform for $3.0 Million Upfront Payment - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 3.35e+006 (%) |
| Held by Institutions | 1.7 (%) |
| Shares Short | 124 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -9.29e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 162.3 % |
| Operating Margin | -5 % |
| Return on Assets (ttm) | 294.5 % |
| Return on Equity (ttm) | -59.4 % |
| Qtrly Rev. Growth | 3.2e+006 % |
| Gross Profit (p.s.) | -73.63 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 5.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 9 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.05 |
| Dividend | 0 |
| Forward Dividend | 166130 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|